Document is current
Any future updates will be listed below
-
Authors
Voiriot, Guillaume https://orcid.org/0000-0003-2236-0288
Argaud, Laurent
Cohen, Yves
Tuffet, Sophie
Chauvelot, Louis
Souweine, Bertrand
Klouche, Kada
Reignier, Jean
Schwebel, Carole
Rouzé, Anahita
Mekontso Dessap, Armand
Bohé, Julien
Megarbane, Bruno
Carvelli, Julien
Navellou, Jean-Christophe
Gibot, Sébastien
Maury, Éric
Dellamonica, Jean
Dequin, Pierre-François
Dessajan, Julien
Armand-Lefèvre, Laurence
Vandenesch, Francois
Verdet, Charlotte
Durand Zaleski, Isabelle
Bérard, Laurence
Rousseau, Alexandra
Tabassome, Simon
Fartoukh, Muriel
Timsit, Jean-François
,
Siaha, Bibi Fabiola Ngaleu
Turpin, Matthieu
Gibelin, Aude
de Montmollin, Nina
Desnos, Cyrielle
Bouadma, Lila
de Montmollin, Etienne
Doman, Marc
Thy, Michael
Sonneville, Romain
Lamara, Fariza
Eczenberg, Michael
Courte, Guilhem
Piton, Gaël
Jeannot, Katy
Cour, Martin
Provent, Marion
Gainnier, Marc
Dauwalder, Olivier
Richard, Jean-Christophe
Jacquier, Hervé
Cambau, Emmanuelle
Baudel, Jean Luc
Tankovic, Jacques
Wallet, Frédéric
Nseir, Saad
Jauréguy, Françoise
Wallet, Florent
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03452826 at ClinicalTrials.govDocuments that mention this clinical trial
Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units (Pre-results)
https://doi.org/10.1136/bmjopen-2020-048187
Combined use of a multiplex PCR and serum procalcitonin to reduce antibiotic exposure in critically ill patients with community-acquired pneumonia: the MULTI-CAP randomized controlled trial
https://doi.org/10.1007/s00134-025-08014-9
-
Funding
Funding for this research was provided by:
Direction Générale de l’offre de Soins
bioMérieux
- License Information
-
More Information
Article History
Received: 10 March 2025
Accepted: 23 June 2025
First Online: 15 July 2025
Declarations
:
: Laurence Armand-Lefèvre received consulting fees from Shionogi and Viatris, and honoraria for lectures from Advanz, Shionogi and Pfizer. In addition, she performed unpaid lectures for BioMérieux and Qiagen. Julien Dessajan received honoraria for lectures from BioMérieux. Isabelle Durand-Zaleski received consulting fees from Bristol Myers Squibb, MSD, Sanofi, Pfizer and Roche. Muriel Fartoukh reported research grants from BioMérieux and personal fees from BioMérieux, Pfizer, SOS Oxygene and Fisher and Paykel. Tabassome Simon reported support for research from BioMérieux, research grants from Astra Zeneca, Bayer, Boehringer, Daiichi Sankyo, Ili-Lilly, GSK, Novartis and Sanofi, and honoraria for lectures from Servier and Novartis. In addition, she reported participation in Data Safety Monitoring Board for Ablative Solutions, Air Liquide, Astra Zeneca, Sanofi, Novartis and 4Living Biotech. Jean-Francois Timsit Simon reported support for research from BioMérieux, and consulting fees from Advanz, Menarini, Pfizer and Merck. In addition, he reported honoraria for lectures from BioMérieux, MundiPharma and Merck. Guillaume Voiriot reported research grants from BioMérieux and SOS Oxygene, and support for attending meetings from Oxyvie. Francois Vandenesch reported been founder and shareholder of Weezion.
